MetaCap

ADMA Biologics (ADMA) vs Iovance Biotherapeutics (IOVA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Iovance Biotherapeutics (IOVA) has outperformed ADMA Biologics (ADMA) over the past year, gaining 208.0% versus a loss of 23.3%. Over five years, ADMA leads with a +808.3% price change compared with -62.7% for IOVA. Iovance Biotherapeutics is the larger company by market cap ($3.19 billion vs $2.92 billion), about 1.1 times the size.

ADMA Biologics converts more of its revenue into profit, with a net margin of 28.8% versus -148.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADMA-23.34%IOVA+208.04%
+594%+254%-87%
Nov 21, 20251 yearNov 20, 2026
ADMA+760.78%IOVA-63.36%
+1514%+673%-168%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADMA versus IOVA key metrics
MetricADMAIOVA
Share price$13.17$6.90
Market cap$2.92B$3.19B
1-day change-1.27%-5.61%
YTD return-27.80%+152.75%
1-year return-23.34%+208.04%
5-year return+808.28%-62.70%
P/E ratio (TTM)17.10—
Forward P/E14.06—
EPS (TTM)$0.77$-0.49
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$510.17M$263.50M
Revenue growth (YoY)+19.63%+60.60%
Net income (latest FY)$146.93M$-390.98M
Gross margin57.39%34.28%
Operating margin37.53%-153.08%
Net margin28.80%-148.38%
52-week high$20.46$15.37
52-week low$7.21$2.08
Distance from 52-week high-35.62%-55.11%
Analyst consensusbuybuy
Avg. price target upside+36.67%+110.14%
Average volume3.23M14.91M
Shares outstanding221.85M462.66M
Employees640975
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IOVA has outperformed ADMA by 231.4 percentage points over the past year.
  • ADMA Biologics is more profitable, keeping 28.8 cents of every revenue dollar as net income versus -148.4 cents for Iovance Biotherapeutics.
  • Iovance Biotherapeutics grew revenue faster in its latest fiscal year (+60.60% vs +19.63%).

About ADMA Biologics

ADMA stock →

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees

About Iovance Biotherapeutics

IOVA stock →

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 975 employees

ADMA vs IOVA FAQ

Which is bigger, ADMA Biologics or Iovance Biotherapeutics?

Iovance Biotherapeutics (IOVA) is larger, with a market capitalization of $3.19B compared with $2.92B for ADMA Biologics (ADMA).

Which stock has performed better over the past year, ADMA or IOVA?

IOVA returned +208.04% over the past 12 months, compared with -23.34% for ADMA (price return, excluding dividends). Past performance does not predict future results.

Are ADMA Biologics and Iovance Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons